Register for email alerts and news feeds:
This journal | BMJ Group
rss
The most recent version of this article was published on 1 October 2006

Thorax. Published Online First: 14 July 2006. doi:10.1136/thx.2006.063271
Copyright © 2006 BMJ Publishing Group Ltd & British Thoracic Society.

Papers

Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis

R Graham Barr 1*, Jean Bourbeau 2, Carlos A Camargo, Jr. 3 and Felix S F Ram 4

1 Columbia University, United States
2 McGill University Health Centre, Canada
3 Massachusetts General Hospital, United States
4 Massey University, New Zealand

* To whom correspondence should be addressed. E-mail: rgb9{at}columbia.edu.

Accepted 16 June 2006


Abstract

Objective: To evaluate the efficacy of tiotropium, a long-acting anticholinergic therapy, on clinical events, symptom scales, pulmonary function and adverse events in stable chronic obstructive pulmonary disease (COPD).

Data sources: A compilation of systematic searches of the Cochrane Trials database, MEDLINE, EMBASE, CINAHL and hand-search of 20 respiratory journals. Missing data were obtained from authors and the manufacturer.

Design: A systematic review of high quality randomised controlled trials.

Review methods: Randomised trials of ≥12 week's duration comparing tiotropium to placebo, ipratropium bromide, or long-acting {beta}2-agonists (LABA). Studies were pooled to yield odds ratios (OR) or weighted mean differences with 95% confidence intervals (CI).

Results: Nine trials (8,002 patients) met inclusion criteria. Tiotropium reduced the odds of a COPD exacerbation (OR 0.73; 95% CI, 0.66 to 0.81) and related hospitalisation (OR 0.68; 95% CI, 0.54 to 0.84) but not pulmonary (OR 0.50; 95% CI, 0.19 to 1.29) or all-cause (OR 0.96; 95% CI, 0.63 to 1.47) mortality compared to placebo and ipratropium. Reductions in exacerbations and hospitalisations compared to LABA were not statistically significant. Similar patterns were evident for quality-of-life and symptom scales. Tiotropium yielded greater increases in FEV1 and FVC from baseline to 6-12 months than did placebo, ipratropium and LABA. Decline in FEV1 over one year was 30 ml (95% CI, 7 to 53 ml) slower with tiotropium than with placebo and ipratropium (data were not available for LABA). Reports of dry mouth and urinary tract infections were increased with tiotropium.

Conclusions: Tiotropium reduced COPD exacerbations and related hospitalisations. In addition, tiotropium improved quality-of-life and symptoms, and may have slowed decline in FEV1. Long-term trials are warranted to evaluate the effects of tiotropium on decline in FEV1 and to clarify its role compared to LABA.

Keywords: bronchodilator agents, cholinergic antagonists, chronic bronchitis, chronic obstructive pulmonary disease, emphysema


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Lee, T. A., Wilke, C., Joo, M., Stroupe, K. T., Krishnan, J. A., Schumock, G. T., Pickard, A. S. (2009). Outcomes Associated With Tiotropium Use in Patients With Chronic Obstructive Pulmonary Disease. Arch Intern Med 169: 1403-1410 [Abstract] [Full Text]  
  • Anzueto, A., Miravitlles, M. (2009). Efficacy of tiotropium in the prevention of exacerbations of COPD. Ther Adv Respir Dis 3: 103-111 [Abstract]  
  • Black, P N, McDonald, C F (2009). Interventions to reduce the frequency of exacerbations of chronic obstructive pulmonary disease. Postgrad. Med. J. 85: 141-147 [Abstract] [Full Text]  
  • Chen, A. M, Bollmeier, S. G, Finnegan, P. M (2008). Long-Acting Bronchodilator Therapy for the Treatment of Chronic Obstructive Pulmonary Disease. The Annals of Pharmacotherapy 42: 1832-1842 [Abstract] [Full Text]  
  • Gross, N. J. (2008). Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation. Mayo Clin Proc. 83: 1241-1250 [Abstract] [Full Text]  
  • Singh, S., Loke, Y. K., Furberg, C. D. (2008). Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. JAMA 300: 1439-1450 [Abstract] [Full Text]  
  • Oba, Y. (2008). Does Tiotropium Reduce Hospitalizations in Chronic Obstructive Pulmonary Disease?. ANN INTERN MED 148: 626-626 [Full Text]  
  • Lin, K., Watkins, B., Johnson, T., Rodriguez, J. A., Barton, M. B. (2008). Screening for Chronic Obstructive Pulmonary Disease Using Spirometry: Summary of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 148: 535-543 [Abstract] [Full Text]  
  • Sridhar, M, Taylor, R, Dawson, S, Roberts, N J, Partridge, M R (2008). A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease. Thorax 63: 194-200 [Abstract] [Full Text]  
  • Wedzicha, J. A., Calverley, P. M. A., Seemungal, T. A., Hagan, G., Ansari, Z., Stockley, R. A., for the INSPIRE Investigators, (2008). The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide. Am. J. Respir. Crit. Care Med. 177: 19-26 [Abstract] [Full Text]  
  • Wilt, T. J., Niewoehner, D., MacDonald, R., Kane, R. L. (2007). Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline. ANN INTERN MED 147: 639-653 [Abstract] [Full Text]  
  • Bourbeau, J., Ford, G., Zackon, H., Pinsky, N., Lee, J., Ruberto, G. (2007). Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 30: 907-913 [Abstract] [Full Text]  
  • Hanania, N. A., Donohue, J. F. (2007). Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators. Proc Am Thorac Soc 4: 526-534 [Abstract] [Full Text]  
  • Soriano, J. B., Barnes, N. C. (2007). Eppur si muove, or COPD treatment success and inflammation. Eur Respir J 30: 409-410 [Full Text]  
  • Chang, J., Mosenifar, Z. (2007). Differentiating COPD From Asthma in Clinical Practice. J Intensive Care Med 22: 300-309 [Abstract]  
  • Beeh, K. M., Derom, E., Kanniess, F., Cameron, R., Higgins, M., van As, A. (2007). Indacaterol, a novel inhaled {beta}2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 29: 871-878 [Abstract] [Full Text]  
  • Shafazand, S. (2007). Review: long acting {beta}2 adrenoceptor agonists are effective in poorly reversible chronic obstructive pulmonary disease. Evid. Based Med. 12: 12-12 [Full Text]  
  • Shafazand, S. (2007). Review: anticholinergics but not {beta}2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD. Evid. Based Med. 12: 13-13 [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Chest Medicine Jobs

Chest Medicine Jobs